1. Scrip
  3. >>Anticancer

Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships

 
• By Dexter Jie Yan

Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.

business partnership
Junshi/Coherus’s anti-PD-1 Loqtorzi gets into swing of partnering for combination therapies • Source: Shutterstock

Having successfully landed their anti-PD-1 Loqtorzi (toripalimab) in the US, Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. are set to jump-start a partnership bonanza for potential combination therapies using the immuno-oncology drug as the backbone.

Key Takeaways

  • Junshi and Coherus’s anti-PD-1 Loqtorzi (toripalimab) was finally approved in the US on 27 October after one and a half years of twists and turns under review.

Loqtorzi went through twists and turns for its biologics license application with the US Food and Drug Administration over the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Kymera Inks CDK2 Deal With Gilead

 
• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

More from Therapy Areas